Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.
about
Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs.AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancerHigh-fidelity of non-small cell lung cancer xenograft models derived from bronchoscopy-guided biopsies.The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations.Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas.The prognostic role of pretreatment epidermal growth factor receptor T790M mutation in advanced non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors.Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations.Differential MicroRNA Expression between EGFR T790M and L858R Mutated Lung Cancer
P2860
Q33621143-CA5A63DF-070B-4F40-97F1-1CBFE6C43796Q34497467-FEA83552-456D-4D20-9F76-7BE35837E528Q35842446-101C171F-E820-4D24-AF7C-7F7FE591C84FQ36103228-D57B10C7-4E35-49BE-BB62-C179B74CDF56Q36477716-D8B2DDD2-95D3-429B-B1B1-B1D6C8D0786AQ37077933-3E6F7B52-89F9-4C75-9FF1-FB28633C9C3AQ37094986-994BC681-5B8D-446A-8C28-5B8B4D1A8F8CQ37269159-A51CD128-F22F-4385-8230-6296912A3B2BQ41233667-17209CFE-61F6-4FED-9E1A-15804AF8B2E2Q41612540-E8ACAB2A-7292-42C6-85C7-C08654CC9D44Q47116265-2ADA3084-13AD-4476-B6B1-FFFC3010CC3DQ49873962-29172A31-523F-44F5-9DD7-F924F521E133Q58772425-58E4C8A3-5F3D-48C0-9835-A7930FDE3D3F
P2860
Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.
@en
Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.
@nl
type
label
Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.
@en
Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.
@nl
prefLabel
Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.
@en
Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.
@nl
P2093
P1433
P1476
Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.
@en
P2093
Geon Kook Lee
Heung Tae Kim
Jin Soo Lee
Jung-Ah Hwang
Youngjoo Lee
P356
10.1016/J.CLLC.2014.09.002
P407
P577
2014-09-28T00:00:00Z